Skip to content
Peptide research

Glutathione

Also known as GSH
Category
Longevity & Anti-Aging
Administration routes
InjectableOral
Regulatory status
Not FDA-approved

The body's master antioxidant, a tripeptide that neutralizes free radicals, aids liver detox, and recycles vitamins C and E. Evidence is strongest for reduced oxidative stress and better blood sugar in elderly diabetics; broader immune and neuroprotective claims rest on thin data. IV use carries real risk, including liver dysfunction and severe reactions from misused skin-lightening use. Not FDA-approved; sold mainly as an unregulated supplement.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Note: Glutathione is a tripeptide (Glu-Cys-Gly) with a non-standard gamma-peptide bond between glutamate and cysteine. It functions primarily as the body's master antioxidant and cellular metabolite rather than as a signaling peptide, but is commonly included in peptide therapy protocols.

Glutathione is a small molecule made of three amino acids (glutamate, cysteine, and glycine) that is naturally produced in every cell of your body. Often called the 'master antioxidant,' it is the most abundant protective molecule inside human cells, present at concentrations 1,000 to 10,000 times higher than most other antioxidants. Glutathione plays a central role in neutralizing free radicals, detoxifying harmful substances, supporting immune function, and maintaining overall cellular health.

How it works in the body

Your body's master antioxidant — a tripeptide (glutamate-cysteine-glycine) present in every cell. It neutralizes free radicals by donating electrons, detoxifies harmful compounds in the liver via glutathione S-transferase enzymes, and regenerates other antioxidants like vitamins C and E.

Research overview

Glutathione is one of the most studied molecules in biochemistry, with over 180,000 scientific publications. Its roles in antioxidant defense, detoxification, and immune cell function are well established. Randomized controlled trials show that oral supplementation at 250-1,000 mg/day raises blood glutathione levels by 17-35% over 1-6 months. Liposomal formulations work faster, achieving up to 40% increases in whole blood levels within two weeks. Clinical studies have shown improved insulin sensitivity in obese and diabetic subjects, reduced oxidative stress markers, up to a 4-fold increase in natural killer cell activity in an uncontrolled 12-person pilot, and, in an exploratory post hoc subgroup, lower HbA1c in elderly diabetic patients. A key challenge is that standard oral glutathione has very poor absorption (below 1%) due to digestive breakdown, making delivery method critical — an experimental N-methylated analogue showed about 16-fold greater oral bioavailability in rats in 2025; this does not establish the same improvement for human liposomal supplements.

Who researches Glutathione?

Commonly researched by

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

  • People researching immune system support

    Studied for immune modulation, antiviral, or antimicrobial properties.

  • People researching longevity and anti-aging interventions

    Studied for effects on aging pathways, cellular health, or lifespan extension.

  • People researching blood sugar regulation

    Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.

Important considerations for

  • Those with Asthma (inhaled form)

    Moderate

    Inhaled glutathione can trigger bronchospasm in asthmatic patients.

  • Those with Organ transplant recipients

    Moderate

    Antioxidant/immune modulation may interfere with immunosuppressive drug efficacy.

Safety & interactions

Do not use if

  • Asthma (inhaled form)

    Moderate

    Inhaled glutathione can trigger bronchospasm in asthmatic patients.

  • Organ transplant recipients

    Moderate

    Antioxidant/immune modulation may interfere with immunosuppressive drug efficacy.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(10)

Rated by level of concern

  • GI side effects: Mild gastrointestinal discomfort, bloating, cramping, and loose stools, especially at higher oral doses

    Low

    PMID 24791752 (Richie et al., Eur J Nutr 2015); PMID 33740389; PMC5808366

  • Allergic reactions: Rare but possible; severe anaphylaxis reported with IV administration (one case in skin lightening review)

    Moderate

    PMC5808366 (Sonthalia et al.)

  • IV-specific risks: 32% adverse event rate in one study including liver dysfunction; injection site reactions; risk of air embolism or sepsis with improper administration

    High

    PMC5808366 (Sonthalia et al.); Philippine FDA Advisory 2011-004 / FDA Advisory No. 2019-182 (fda.gov.ph)

  • Zinc depletion: Long-term or high-dose supplementation may reduce zinc levels through mineral chelation/interaction

    Theoretical

    No primary human evidence located; mechanism-based (thiol-metal binding). Not reported in PMC5808366.

  • Potential thyroid effects: Case reports and preliminary studies suggest possible thyroid dysfunction with chronic high-dose use, particularly IV formulations

    Low

    Philippine FDA Advisory 2011-004; PMC5808366

  • Chemotherapy interference: May reduce effectiveness of alkylating agents and platinum-based chemotherapy (cisplatin) by enhancing drug conjugation and efflux

    Low

    PMID 7799029 (Cascinu, JCO 1995); PMID 12177109 (Cascinu, JCO 2002); Leal, Cancer 2014 (N08CA phase 3)

  • Asthma exacerbation: Inhaled glutathione may worsen asthma symptoms in susceptible individuals

    High

    PMID 9279219 (Marrades et al., Am J Respir Crit Care Med 1997;156:425-30)

  • Pregnancy/lactation: Insufficient safety data; not recommended during pregnancy or breastfeeding without medical supervision

    Moderate

    Absence of data in trial populations: PMID 24791752; PMID 33740389; PMC5808366

  • Skin lightening misuse: Unregulated IV use for skin lightening has led to severe adverse events including Stevens-Johnson syndrome and toxic epidermal necrolysis

    High

    Philippine FDA Advisory 2011-004 and FDA Advisory No. 2019-182 (fda.gov.ph); PMC5808366; case report: 'Intravenous Glutathione and Vitamin Supplementation Causing Stevens-Johnson Syndrome', J Burn Care Res

  • Rebound oxidative stress: Abrupt cessation after prolonged high-dose supplementation may temporarily reduce endogenous GSH production

    Theoretical

    PMID 24791752 (washout data, Richie et al. 2015); PMID 28436395

Interaction summary(8)

Rated by direction with this peptide

  • Cisplatin (platinum chemotherapy)

    ProtectiveModerate

    IV glutathione reduced cisplatin-induced peripheral neurotoxicity (neurotoxicity in 4/24 vs 16/18 on placebo) without compromising antitumor activity in a randomized double-blind placebo-controlled trial in advanced gastric cancer, with supporting toxicity and quality-of-life benefit in ovarian cancer. This is an oncologist-supervised IV protocol given alongside chemotherapy, not self-supplementation — do not extrapolate to oral supplements.

    PMID 7799029 (Cascinu et al., J Clin Oncol 1995;13:26-32); Smyth et al., Ann Oncol 1997;8:569-73

  • Oxaliplatin

    ProtectiveModerate

    A randomized double-blind placebo-controlled trial (n=52) of IV glutathione during oxaliplatin-based chemotherapy in advanced colorectal cancer found significantly less neuropathy at higher cumulative doses (3 vs 8 with severe neuropathy, P=.004) and concluded glutathione does not reduce oxaliplatin's clinical activity. Later guideline reviews still rate the overall chemotherapy-induced-neuropathy evidence as inconsistent. Oncologist-supervised IV use only.

    PMID 12177109 (Cascinu et al., J Clin Oncol 2002;20:3478-83)

  • Paclitaxel / carboplatin

    NeutralLow

    The phase 3 randomized double-blind placebo-controlled NCCTG/Alliance N08CA trial found glutathione did not prevent paclitaxel/carboplatin-induced peripheral neuropathy — the protective effect seen with cisplatin and oxaliplatin did not carry over to this regimen. Useful as a boundary on the protective claim.

    Leal et al., Cancer 2014 (trial N08CA), doi:10.1002/cncr.28654

  • Alkylating agents (e.g. cyclophosphamide, melphalan, chlorambucil)

    CautionTheoretical

    Glutathione S-transferase-mediated conjugation and MRP efflux are established mechanisms of tumor resistance to alkylating agents, so raising intracellular glutathione could in principle blunt efficacy. Mechanism-based only — no human trial has demonstrated reduced response, and the platinum trials that did measure antitumor activity found none lost. Flag for oncologist discussion; do not present as a demonstrated interaction.

    Mechanistic (GST/MRP-mediated tumor resistance); no confirmatory human data identified

  • Nebulized/inhaled use in asthma or sulfite-sensitive patients

    CautionHigh

    Nebulized glutathione produced marked bronchoconstriction (FEV1 -19%, Rrs +61%), cough, and breathlessness in mild asthmatics in a randomized double-blind crossover trial, tracking sulfite sensitivity rather than methacholine responsiveness and reversed by salbutamol. Inhaled glutathione should be avoided in asthma and sulfite sensitivity. Applies to the inhaled route only.

    PMID 9279219 (Marrades et al., Am J Respir Crit Care Med 1997)

  • Acetaminophen (paracetamol)

    ProtectiveTheoretical

    Acetaminophen hepatotoxicity is driven by NAPQI depleting hepatic glutathione, and repletion via the precursor N-acetylcysteine is the established antidote — but there is no human evidence that oral or IV glutathione supplements protect against acetaminophen toxicity, and no one should substitute a glutathione supplement for NAC. Overdose is a medical emergency requiring NAC.

    Established pharmacology of NAPQI detoxification and the NAC antidote; no human data for glutathione supplements in this setting

  • N-acetylcysteine and glycine (GlyNAC)

    SynergisticLow

    Supplying the rate-limiting precursors cysteine and glycine restores deficient de novo glutathione synthesis and, in pilot randomized work in type 2 diabetes and older adults, improved redox status, oxidative-damage markers, and insulin resistance. Pilot-scale evidence only.

    PMID 35052658 (GlyNAC pilot in T2DM)

  • Unregulated cosmetic IV infusions (skin lightening clinics)

    CautionHigh

    Multiple regulators warn that high-dose IV glutathione given for skin whitening has been linked to liver dysfunction (32% in the one published IV trial), anaphylaxis, Stevens-Johnson syndrome/TEN, renal and thyroid dysfunction, and fatal air embolism or sepsis from non-sterile administration; no agency has approved this use.

    Philippine FDA Advisory No. 2019-182 and 2011-004 (fda.gov.ph); PMC5808366 (Sonthalia et al.)

Known risks(10)

  • GI side effects: Mild gastrointestinal discomfort, bloating, cramping, and loose stools, especially at higher oral doses

  • Allergic reactions: Rare but possible; severe anaphylaxis reported with IV administration (one case in skin lightening review)

  • IV-specific risks: 32% adverse event rate in one study including liver dysfunction; injection site reactions; risk of air embolism or sepsis with improper administration

  • Zinc depletion: Long-term or high-dose supplementation may reduce zinc levels through mineral chelation/interaction

  • Potential thyroid effects: Case reports and preliminary studies suggest possible thyroid dysfunction with chronic high-dose use, particularly IV formulations

  • Chemotherapy interference: May reduce effectiveness of alkylating agents and platinum-based chemotherapy (cisplatin) by enhancing drug conjugation and efflux

  • Asthma exacerbation: Inhaled glutathione may worsen asthma symptoms in susceptible individuals

  • Pregnancy/lactation: Insufficient safety data; not recommended during pregnancy or breastfeeding without medical supervision

  • Skin lightening misuse: Unregulated IV use for skin lightening has led to severe adverse events including Stevens-Johnson syndrome and toxic epidermal necrolysis

  • Rebound oxidative stress: Abrupt cessation after prolonged high-dose supplementation may temporarily reduce endogenous GSH production

Drug interactions(6)

  • Cisplatin and platinum-based chemotherapeutics

    Major — Consult oncologist before any concurrent use

    GSH conjugates cisplatin via GST enzymes and facilitates MRP2-mediated efflux, potentially reducing anti-tumor efficacy. Three mechanisms proposed: GSH as MRP2 cofactor for cisplatin efflux, redox cytoprotection, and copper chelation. Paradoxically, IV GSH may reduce cisplatin-induced neurotoxicity.

  • Alkylating agents (cyclophosphamide, melphalan)

    Major — Avoid concurrent use without oncology guidance

    GSH and GST-mediated conjugation can detoxify alkylating agents, contributing to chemoresistance. Elevated intracellular GSH is a recognized mechanism of alkylating agent resistance in cancer cells.

  • Acetaminophen (paracetamol)

    Moderate — Supportive interaction; relevant in overdose context

    GSH detoxifies the hepatotoxic metabolite NAPQI (N-acetyl-p-benzoquinone imine) produced by CYP2E1 metabolism of acetaminophen. GSH supplementation may be protective, but GSH depletion from high acetaminophen doses leads to liver damage. NAC (GSH precursor) is the standard antidote for acetaminophen overdose.

  • Nitroglycerin and organic nitrates

    Moderate — Monitor for altered nitrate efficacy

    GSH is required for the biotransformation of nitroglycerin to nitric oxide. GSH depletion may contribute to nitrate tolerance. Supplementation could theoretically affect nitrate drug response.

  • Immunosuppressants (cyclosporine, tacrolimus)

    Moderate — Monitor immune parameters in transplant patients

    GSH modulates immune cell function including T-cell proliferation and NK cell activity. Enhanced immune function from GSH supplementation could theoretically counteract immunosuppressive therapy.

  • Alcohol (ethanol)

    Minor — Supplementation may be supportive but is not a substitute for alcohol reduction

    Chronic alcohol consumption depletes hepatic GSH stores, contributing to alcoholic liver disease. GSH supplementation may be beneficial but does not offset ongoing alcohol-induced damage.

Research & benefits

Evidence base

Evidence Level
Moderate-to-Strong
Total Studies
50
Human Studies
30

Strong biochemical evidence for antioxidant, detoxification, and immune roles. Multiple RCTs demonstrate that oral and liposomal glutathione supplementation significantly raises body stores of GSH across blood compartments. Clinical efficacy shown for immune enhancement (NK cell cytotoxicity), insulin sensitivity improvement, and oxidative stress reduction. However, some trials show no change in systemic oxidative stress biomarkers in healthy adults, suggesting benefits are most pronounced in GSH-depleted or metabolically stressed populations. Long-term safety data beyond 6 months remains limited.

Researched for(8)

Rated by confidence in the evidence

  • Master antioxidant defense — neutralizes reactive oxygen/nitrogen species (ROS/RNS), reduces hydrogen peroxide, organic hydroperoxides, and lipid peroxides

    Medium

    Human trials raise glutathione levels reliably; effects on oxidative damage markers are mixed.

    PMID 24791752 (Richie et al., Eur J Nutr 2015); PMID 33740389 (Sondergard et al., 2021 — null for oxidative-stress markers); PMC9137531 (Kalamkar et al., Antioxidants 2022)

  • Xenobiotic and toxin detoxification — conjugates electrophilic compounds via glutathione S-transferases (GSTs) for excretion; shown to reduce blood mercury by 39% in 30 days

    Speculative

    The 39% mercury reduction figure comes from one small uncontrolled study, not a controlled trial.

    Miller & Blair, Townsend Letter (open-label, n=7, non-indexed — cited only to identify the origin of the 39% figure, not as support for it): https://townsendletter.com/absorption-safety-and-detoxification-effects-of-oral-liposomal-glutathione/

  • Immune system enhancement — NK cell cytotoxicity increased up to 400%, lymphocyte proliferation increased up to 60%

    Medium

    One RCT found roughly doubled NK activity. A separate uncontrolled 12-person pilot reported up to 400% higher NK cytotoxicity and 60% higher lymphocyte proliferation; these were laboratory immune markers.

    PMID 24791752 (Richie et al., Eur J Nutr 2015); NCT01044277

  • Improved insulin sensitivity in obese and type 2 diabetic subjects

    Medium

    Small double-blind trial (n=20) using gold-standard clamp method showed improved insulin sensitivity.

    PMID 33740389 (Sondergard et al., 2021, double-blind RCT, n=20); PMID 35052658 (GlyNAC pilot, precursor not glutathione)

  • Reduced oxidative damage and improved HbA1c in elderly type 2 diabetic patients

    High

    A randomized study recruited adults aged 30–78 with type 2 diabetes. The HbA1c benefit in participants over 55 came from a post hoc subgroup analysis.

    PMC9137531 (Kalamkar et al., Antioxidants 2022 — 'Randomized Clinical Trial of How Long-Term Glutathione Supplementation Offers Protection from Oxidative Damage and Improves HbA1c in Elderly Type 2 Diabetic Patients')

  • Cellular redox homeostasis — maintains GSH/GSSG ratio critical for protein function, gene expression, cell cycle regulation, and apoptosis control

    Medium

    Central to cell biology, but human data covers only a reversible blood biomarker shift.

    PMID 24791752 (Richie et al., Eur J Nutr 2015 — biomarker endpoint only)

  • Neuroprotective potential — may reduce cisplatin-induced neurotoxicity; under investigation for Parkinson's and neurodegenerative diseases

    Medium

    Reduced cisplatin nerve damage in one RCT; Parkinson's disease trials showed no benefit.

    PMID 7799029 (Cascinu et al., J Clin Oncol 1995); Smyth, Ann Oncol 1997;8:569-73; Leal, Cancer 2014 (N08CA), doi:10.1002/cncr.28654; PMID 26230671; PMID 28436395 (Mischley)

  • Skin health — inhibits melanin synthesis via tyrosinase inhibition; studied for hyperpigmentation

    Low

    Small short trials show modest lightening, but reviewers say evidence overall remains unconvincing.

    PMC5808366 (Sonthalia et al., review of glutathione for skin lightening)

Benefits(8)

  • Master antioxidant defense — neutralizes reactive oxygen/nitrogen species (ROS/RNS), reduces hydrogen peroxide, organic hydroperoxides, and lipid peroxides

    Forman et al. 2009 (PMC2696075); mechanistic biochemistry well-established across thousands of studies

  • Xenobiotic and toxin detoxification — conjugates electrophilic compounds via glutathione S-transferases (GSTs) for excretion; shown to reduce blood mercury by 39% in 30 days

    Liposomal GSH detoxification study; GST conjugation pathways extensively characterized

  • Immune system enhancement — NK cell cytotoxicity increased up to 400%, lymphocyte proliferation increased up to 60%

    Sinha et al. 2018 (PMID 28853742); Richie et al. 2015 (PMID 24791752)

  • Improved insulin sensitivity in obese and type 2 diabetic subjects

    Søndergård et al. 2021 (PMID 33740389) — 1000 mg/day for 3 weeks improved whole-body insulin sensitivity

  • Reduced oxidative damage and improved HbA1c in elderly type 2 diabetic patients

    Kalamkar et al. 2022 (PMID 35624890) — 500 mg/day for 6 months; significant effect sizes (Cohen's d = 1.01 for GSH, -1.07 for 8-OHdG)

  • Cellular redox homeostasis — maintains GSH/GSSG ratio critical for protein function, gene expression, cell cycle regulation, and apoptosis control

    Lushchak 2012 (PMC3303626); Franco et al. 2014 (Frontiers in Pharmacology)

  • Neuroprotective potential — may reduce cisplatin-induced neurotoxicity; under investigation for Parkinson's and neurodegenerative diseases

    Multiple preclinical and early clinical studies; IV GSH studied in Parkinson's disease

  • Skin health — inhibits melanin synthesis via tyrosinase inhibition; studied for hyperpigmentation

    Multiple RCTs reviewed in PMC11862975 (2025 narrative review)

Key studies(8)

  1. Richie JP Jr, Nichenametla S, Neidig W, Calcagnotto A, Haley JS, Schell TD, Muscat JE

    European Journal of Nutrition

    2015

    Oral GSH (250 or 1000 mg/day) increased GSH levels 30-35% in erythrocytes, plasma, and lymphocytes, and 260% in buccal cells at 6 months. NK cell cytotoxicity doubled in the high-dose group at 3 months. Effects reversed after cessation.

  2. Sinha R, Sinha I, Calcagnotto A, Trushin N, Haley JS, Schell TD, Richie JP Jr

    European Journal of Clinical Nutrition

    2018

    The 12-person pilot reported maximum increases at two weeks of 40% in whole blood, 25% in erythrocytes, 28% in plasma and 100% in PBMCs. Immune markers also increased. It lacked a placebo group.

  3. Søndergård SD, Cintin I, Kuhlman AB, Morville TH, Bergmann ML, Kjær LK, Poulsen HE, Giustarini D, Rossi R, Dela F, Helge JW, Larsen S

    Applied Physiology, Nutrition, and Metabolism

    2021

    1000 mg/day oral GSH significantly improved whole-body insulin sensitivity in obese subjects with and without T2DM. Skeletal muscle GSH increased ~19%. No changes in oxidative stress markers, suggesting mechanisms beyond antioxidant activity.

  4. Kalamkar S, et al.

    Antioxidants (Basel)

    2022

    500 mg/day oral GSH significantly increased blood GSH (Cohen's d=1.01) and decreased oxidative damage marker 8-OHdG (d=-1.07) within 3 months. A post hoc subgroup analysis found lower HbA1c in participants over 55 (d=-0.41); this exploratory result needs confirmation.

  5. Forman HJ, Zhang H, Rinna A

    Molecular Aspects of Medicine

    2009

    Definitive review of GSH biosynthesis (GCL and GS enzymes), antioxidant roles (GPx, GST, GR enzyme systems), redox signaling, measurement methods (DTNB recycling, HPLC), and clinical significance in diseases including cystic fibrosis, HIV, and pulmonary fibrosis.

  6. Lushchak VI

    Journal of Amino Acids

    2012

    Comprehensive analysis of GSH homeostasis, its roles as nucleophile and reductant, enzyme cofactor functions, and potential medical intervention targets including cancer therapy (BSO-mediated GSH depletion) and neurodegenerative diseases.

  7. Various

    Pharmaceutics

    2025

    An experimental N-methylated analogue showed 16.8-fold longer plasma half-life and 16.1-fold greater oral bioavailability in rats. Human absorption, efficacy and safety remain unestablished.

  8. Various

    PMC

    2025

    Oral and topical GSH generally safe. IV GSH for skin lightening showed 32% adverse event rate including liver dysfunction and one anaphylaxis case. Long-term systemic effects not yet thoroughly researched. Health authorities warn against unregulated IV use.

What research suggests over time

  • Weeks 2-4

    Multiple human RCTs

    Erythrocyte and plasma GSH levels rising with oral or liposomal supplementation.

  • Months 2-3

    Eur J Nutr / Eur J Clin Nutr

    ~30-40% increase in whole-body GSH stores; liposomal forms reach 100-200% increases in PBMCs by 1-2 months.

  • Long-term

    Multiple human RCTs

    Improved insulin sensitivity in obese subjects (Appl Physiol Nutr 2021); sustained antioxidant capacity with continued supplementation; effects regress on discontinuation.

Regulation & availability

Why researchers look at it

The most abundant antioxidant inside human cells — present at 1,000-10,000x the concentration of most others — with an RCT showing higher blood glutathione and roughly doubled NK activity, while larger immune-marker increases came from an uncontrolled 12-person pilot. The historic barrier was <1% oral absorption, but an experimental N-methylated analogue showed about 16-fold greater oral bioavailability in rats; comparable human results have not been established. If these delivery advances hold up in larger trials, glutathione could shift from a niche IV-clinic supplement to mainstream immune and metabolic support.

Estimated cost
$20-60/mo oral; $100-300/IV session; $50-100/mo liposomal
FDA status
Glutathione is not FDA-approved as a drug. Reduced glutathione is sold as a dietary supplement; no FDA-approved reduced-glutathione systemic drug was identified. FDA ceased evaluating GRN 244 at the notifier's request; resubmission GRN 293 received a no-questions response in December 2009 for specified food uses. This is not drug approval or authorization for injection. Glutathione is in Category 1 under both 503A and 503B interim policies, subject to their conditions; while FDA evaluates it, pharmacies may compound it for an individual patient's prescription under the 503A policy. Compounded glutathione has not been reviewed by FDA for safety or effectiveness. FDA warns against using dietary-supplement-grade ingredients in injectables.
WADA status
Glutathione itself is not named as prohibited on WADA's 2026 list. Administration can still be prohibited: IV infusions or injections above the M2.2 volume limit within a 12-hour period are prohibited, except during legitimate hospital treatment, surgery or clinical diagnostic investigations. Other ingredients must also be checked. Endogenous origin and GRAS status do not determine anti-doping permission.
Prescribability
Available without prescription as an oral dietary supplement (capsules, tablets, sublingual, liposomal forms). IV and injectable formulations are available through compounding pharmacies with a physician's order. N-acetylcysteine (NAC), a GSH precursor, is also widely available OTC.
Availability
Widely available as an over-the-counter dietary supplement in multiple forms: standard oral capsules/tablets (reduced L-glutathione), liposomal oral formulations (significantly improved bioavailability), sublingual tablets, and N-acetylcysteine (NAC) as a precursor. IV glutathione available through compounding pharmacies, integrative medicine clinics, and IV therapy centers with physician oversight. Novel delivery systems including micellar (LipoMicel) and advanced liposomal (LipoDuo) formulations became available in 2025-2026 with dramatically improved bioavailability. Standard oral GSH has bioavailability below 1%; liposomal forms achieve approximately 6x higher peak plasma concentrations.

International status

  • EU

    Available as supplement

  • US

    Glutathione is not FDA-approved. FDA is evaluating it for its list of bulk substances pharmacies may use (Category 1), and in the meantime pharmacies may compound it for an individual patient's prescription. Compounded Glutathione has not been reviewed by FDA for safety or effectiveness.

  • Japan

    Approved pharmaceutical (Tathion) for chemical/drug toxicity

  • Worldwide

    Widely available as dietary supplement

Regulatory timeline(9)

  1. Pre-2000
    Glutathione biochemistry extensively characterized; established as the primary intracellular antioxidant and detoxification molecule across all mammalian cells
  2. 2008
    GRN 244 was filed in February 2008; FDA ceased evaluation in May at the notifier's request. Resubmission GRN 293 received a no-questions response for specified food uses in December 2009.
  3. 2009
    Forman et al. publish comprehensive review of GSH protective roles, biosynthesis, and measurement in Molecular Aspects of Medicine (PMC2696075)
  4. 2014-2015
    Richie et al. publish landmark RCT (PMID 24791752) demonstrating oral GSH supplementation effectively raises body stores — first rigorous proof of oral efficacy
  5. 2017-2018
    Sinha et al. report increased glutathione and immune-function markers in a 12-person liposomal pilot. The study did not compare liposomal glutathione directly with standard oral glutathione.
  6. 2020-2022
    Clinical trials expand: GSH shown to improve insulin sensitivity (Søndergård 2021), protect elderly diabetics from oxidative damage (Kalamkar 2022), and support HIV patient immune function
  7. 2019
    FDA issues advisory highlighting concerns about using dietary supplement-grade glutathione to compound sterile injectable formulations
  8. 2024-2025
    Narrative reviews assess skin-lightening safety profile; Philippine FDA warnings against unregulated IV use; an experimental N-methylated GSH analogue shows approximately 16-fold greater oral bioavailability in rats
  9. 2026
    Advanced delivery systems (LipoMicel, LipoDuo) enter market with dramatically improved oral bioavailability; randomized crossover trials validate novel formulations; ongoing ClinicalTrials.gov studies continue

Sources & FAQs

Research sources(14)

  1. PubMed — Richie et al. 2015 (PMID 24791752): Oral GSH RCT
  2. PubMed — Sinha et al. 2018 (PMID 28853742): Liposomal GSH immune function
  3. PubMed — Søndergård et al. 2021 (PMID 33740389): GSH and insulin sensitivity
  4. PubMed — Kalamkar et al. 2022 (PMID 35624890): GSH in elderly T2DM
  5. PMC — Forman et al. 2009 (PMC2696075): GSH protective roles review
  6. PMC — Lushchak 2012 (PMC3303626): GSH homeostasis and functions
  7. PMC — 2025 (PMC11945201): N-methylated GSH bioavailability
  8. PMC — 2025 (PMC11862975): GSH skin lightening safety review
  9. FDA GRAS Notice GRN 000293: No-questions response for specified glutathione food uses; GRN 244 evaluation was discontinued at the notifier's request.
  10. FDA Drug Compounding Advisory: Concerns re glutathione in sterile injectables
  11. ClinicalTrials.gov NCT01044277: Oral GSH supplementation trial
  12. ClinicalTrials.gov NCT02278822: Liposomal GSH supplementation trial
  13. WebMD Glutathione monograph: Uses, risks, and interactions
  14. GlobalDRO / WADA Prohibited List 2025: Anti-doping status reference

Frequently asked questions(6)

What is glutathione and why is it called the 'master antioxidant'?

Glutathione is a tripeptide (gamma-L-glutamyl-L-cysteinyl-glycine) found in virtually every cell of the body at millimolar concentrations (1-10 mM). It earned the 'master antioxidant' title because it directly neutralizes reactive oxygen species, regenerates other antioxidants (vitamins C and E), serves as a cofactor for critical antioxidant enzymes (glutathione peroxidase, glutathione S-transferase), and maintains the cellular redox balance essential for all biological functions.

Is oral glutathione actually absorbed, or is it destroyed in the gut?

Standard oral glutathione has very low bioavailability (below 1%) due to enzymatic degradation in the GI tract and poor membrane permeability. However, RCTs show that daily standard oral GSH significantly raises blood GSH levels over weeks to months. Liposomal formulations dramatically improve absorption — achieving up to 6x higher plasma concentrations and measurable increases within 1-2 weeks. A 2025 experimental N-methylated analogue showed about 16-fold greater oral bioavailability in rats; this has not established improved absorption in humans.

What is the difference between oral, liposomal, and IV glutathione?

Oral GSH (capsules/tablets) is most accessible but has the lowest bioavailability. Liposomal GSH encapsulates the molecule in phospholipid vesicles that protect it from GI degradation and enhance cellular uptake — achieving faster, higher blood levels. IV glutathione bypasses the GI tract entirely for 100% bioavailability and immediate systemic distribution, but carries higher risks (injection site reactions, potential anaphylaxis) and requires clinical supervision.

Can I take glutathione with chemotherapy drugs?

This requires careful medical supervision. Glutathione can potentially reduce the effectiveness of certain chemotherapy drugs (especially cisplatin) by conjugating and detoxifying them. Elevated GSH combined with high GST expression can increase chemotherapy drug efflux. However, some studies suggest IV GSH may reduce cisplatin-induced neurotoxicity. Always consult your oncologist before combining glutathione with any cancer therapy.

How long does it take to see effects from glutathione supplementation?

Liposomal GSH can raise blood levels within 1-2 weeks (40% increase in whole blood, up to 400% increase in NK cell cytotoxicity at 2 weeks). Standard oral GSH shows significant increases at 1-3 months, with maximal effects at 6 months. IV glutathione provides immediate effects within hours. Clinical outcomes like improved insulin sensitivity have been observed within 3 weeks.

Is glutathione safe for long-term use?

Oral glutathione appears safe for at least 6 months at the doses tested in RCTs. Long-term safety beyond 6 months is not well-characterized. Potential concerns include zinc depletion with chronic use and possible thyroid effects at high doses. IV glutathione carries higher risks and is not recommended for unsupervised long-term use.